- Home
- OABI vs LRMR Comparison
OABI vs LRMR Comparison
Compare OABI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | LRMR |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 89 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.4M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | OABI | LRMR |
|---|---|---|
| Price | $2.32 | $3.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.50 | ★ $16.50 |
| AVG Volume (30 Days) | 562.9K | ★ 2.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.42 | N/A |
| Revenue Next Year | $64.69 | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $2.72 |
| 52 Week High | $2.79 | $6.42 |
Technical Indicators
Market Signals| Indicator | OABI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 49.00 |
| Support Level | $1.75 | $3.02 |
| Resistance Level | $2.70 | $3.77 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 54.91 | 55.51 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.